International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18

被引:39
作者
Chie, Wei-Chu [1 ]
Blazeby, Jane M. [2 ]
Hsiao, Chin-Fu [3 ]
Chiu, Herng-Chia [4 ]
Poon, Ronnie T. [5 ]
Mikoshiba, Naoko [6 ]
Al-Kadhimi, Gillian [7 ]
Heaton, Nigel [7 ]
Calara, Jozer [7 ]
Collins, Peter [8 ]
Caddick, Katharine [8 ]
Costantini, Anna [12 ]
Vilgrain, Valerie [9 ,10 ]
Trinquart, Ludovic [11 ]
Chiang, Chieh [3 ]
机构
[1] Natl Taiwan Univ, Coll Publ Hlth, Dept Publ Hlth, Grad Inst Epidemiol & Prevent Med, Taipei 10055, Taiwan
[2] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England
[3] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Clin Trial Stat, Zhunan, Taiwan
[4] Kaohsiung Med Univ, Grad Inst Healthcare Adm, Kaohsiung, Taiwan
[5] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[6] Univ Tokyo, Grad Sch Med, Dept Adult Nursing Palliat Care Nursing, Tokyo, Japan
[7] Kings Coll Hosp London, Inst Liver Studies, London SE5 8RX, England
[8] Univ Hosp Bristol NHS Fdn Trust, Dept Hepatol, Bristol, Avon, England
[9] Hop Beaujon, APHP, Dept Radiol, Clichy, France
[10] Univ Paris Diderot, INSERM, U773, Ctr Rech Biomed Bichat Beaujon,CRB3, Paris, France
[11] Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin, F-75181 Paris, France
[12] Univ Roma La Sapienza, Fac Med & Psychol, Rome, Italy
关键词
HEPATOCELLULAR-CARCINOMA; FUNCTIONAL ASSESSMENT; CLINICAL-TRIALS; QLQ-C30;
D O I
10.1002/hep.24798
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This international field validation study examined the psychometric properties and clinical validity of the European Organization for Research and Treatment of Cancer (EORTC) questionnaire module for hepatocellular carcinoma (HCC), the EORTC quality-of-life questionnaire (QLQ)-HCC18. The EORTC QLQ-HCC18 was administered with the core questionnaire, the EORTC QLQ-C30, to 272 patients from seven centers in 6 countries. Patient acceptability of the module was examined with a debriefing questionnaire, and psychometric and clinical properties were assessed. Multitrait scaling analyses confirmed the hypothesized scale structure without any scaling error, and the fatigue scale demonstrated satisfactory internal consistency. The test-retest reliability scores were high for all scales, except abdominal swelling and sexual interest. The correlations between all scales of the QLQ-HCC18 and the QLQ-C30 were low or moderate, and many scales could distinguish patients with different clinical conditions. The module demonstrated responsiveness to clinical change in pain before and after surgery and some borderline change in patients undergoing systemic treatment. Conclusion: The EORTC QLQ-HCC18 can be used as a supplementary module for the EORTC QLQ-C30 in clinical trials for patients with HCC. (HEPATOLOGY 2012)
引用
收藏
页码:1122 / 1129
页数:8
相关论文
共 18 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
American Association for the Study of Liver Disease (AASLD) Guidelines, AM ASS STUD LIV DIS
[3]   New therapies for hepatocellular carcinoma [J].
Avila, M. A. ;
Berasain, C. ;
Sangro, B. ;
Prieto, J. .
ONCOGENE, 2006, 25 (27) :3866-3884
[4]   Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18 [J].
Blazeby, JM ;
Currie, E ;
Zee, BCY ;
Chie, WC ;
Poon, RT ;
Garden, OJ .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) :2439-2444
[5]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[6]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[7]  
Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
[8]   Health-Related Quality of Life in Patients With Hepatocellular Carcinoma: A Systematic Review [J].
Fan, Sheng-Yu ;
Eiser, Christine ;
Ho, Ming-Chih .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (07) :559-564
[9]  
Fayers P., 2001, EORTC QLQ C30 SCORIN, V3rd ed.
[10]   Transplantation for hepatocellular carcinoma: The Milan criteria and beyond [J].
Freeman, Richard B., Jr. .
LIVER TRANSPLANTATION, 2006, 12 (11) :S8-S13